Education
About Us
Working with TipRanks
Follow Us
UCB SA (UCBJF)
:UCBJF
UCBJF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$112.70 - $204.00
Previous CloseN/A
Volume200.00
Average Volume (3M)108.00
Market Cap
$35.64B
Enterprise Value$29.66B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)1.39B
Price to Earnings (P/E)30.8
Beta0.53
Next Earnings
Jul 24, 2025EPS Estimate
3.89Last Dividend Ex-Date
Apr 26, 2024Dividend Yield0.53%
Share Statistics
EPS (TTM)6.07
Shares Outstanding194,505,660
10 Day Avg. Volume75
30 Day Avg. Volume108
Standard Deviation0.09
R-Squared0.05
Alpha0.01
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)N/A
Price to Sales (P/S)3.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$216.45Price Target Upside12.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceUCB is expected to exceed consensus expectations for Bimzelx's global sales and US sales in 2025, reflecting strong patient adoption.
Product AdoptionBimzelx is expected to have meaningful adoption due to its differentiation from Cosentyx.
Regulatory ApprovalAnalysts are optimistic about Bimzelx's anticipated FDA approval for hidradenitis suppurativa.
Bears Say
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
15.96% Mutual Funds
<0.01% Other Institutional Investors
76.82% Public Companies and
Individual Investors
UCBJF FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was $112.70 and its highest was $204.00 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is $35.64B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Jul 24, 2025 which is in 143 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Feb 27, 2025. The company reported $2.939 earnings per share for the quarter, beating the consensus estimate of $2.687 by $0.252.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Undervalued.
Does UCB SA pay dividends?
UCB SA pays a Annually dividend of $0.989 which represents an annual dividend yield of 0.53%. See more information on UCB SA dividends here
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 3.89.
How many shares outstanding does UCB SA have?
UCB SA has 194,505,660 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of $2.939 in its last earnings report, beating expectations of $2.687. Following the earnings report the stock price went down -3.359%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in UCBJF
---
Company Description
UCB SA
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Evenity (osteoporosis), and Nayzilam (cluster seizures).
---
UCBJF Stock 12 Month Forecast
Average Price Target
$216.45
▲(12.73% Upside)
Technical Analysis
Best Analysts Covering UCBJF
1 Year
1 Year Success Rate
11/11 ratings generated profit
1 Year Average Return
+40.98%
assigned a buy rating 5 months ago
Copying Peter Verdult's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +40.98% per trade.
---